# Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

> **NCT06379360** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 77 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Hypomethylating agent, Azacitidine or Decitabine

## Key facts

- **NCT ID:** NCT06379360
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2028-12-31
- **Target enrollment:** 77 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06379360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06379360, "Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06379360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*